8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 3, 2026·SEC
InspireMD, Inc.(NSPR)Earnings, Financials & Key Ratios
NSPR•NASDAQ
Price updated Jun 19, 2026
AboutInspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Show more
- Revenue$9M+28.1%
- EBITDA-$49M-46.4%
- Net Income-$49M-52.4%
- EPS (Diluted)-0.76
- Gross Margin29.5%+37.3%
- EBITDA Margin-541.66%-14.3%
- Operating Margin-546.97%-14.4%
- Net Margin-543.33%-19.0%
- ROE-106.88%-26.2%
NSPR Key Insights
InspireMD, Inc. (NSPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 29.3%
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 35.8% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 75.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NSPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NSPR Price & Volume
InspireMD, Inc. (NSPR) stock price & volume — 10-year historical chart
Loading chart...
NSPR Growth Metrics
InspireMD, Inc. (NSPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years14.54%
5 Years29.29%
3 Years20.19%
TTM28.11%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-52.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1.28%
Return on Capital
10 Years-135.61%
5 Years-76.02%
3 Years-84.16%
Last Year-100.41%
NSPR Recent Earnings
InspireMD, Inc. (NSPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.16+15.8%
$0.19
Rev
$3M+25.8%
$3M
Q2 2026
Mar 18, 2026Metric
Actual
Est
EPS
$0.14+36.4%
$0.22
Rev
$3M+19.9%
$3M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.17+0.0%
$0.17
Rev
$3M-3.9%
$3M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.26-8.3%
$0.24
Rev
$2M+1.1%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.16vs $0.19+15.8% | $3Mvs $3M+25.8% |
| Q2 2026 | Mar 18, 2026 | $0.14vs $0.22+36.4% | $3Mvs $3M+19.9% |
| Q4 2025 | Nov 4, 2025 | $0.17vs $0.17+0.0% | $3Mvs $3M-3.9% |
| Q3 2025 | Aug 4, 2025 | $0.26vs $0.24-8.3% | $2Mvs $2M+1.1% |
Based on last 12 quarters of dataView full earnings history →
NSPR Peer Comparison
InspireMD, Inc. (NSPR) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ELMD | 320.27M | 38.68 | 44.98 | 16.97% | 14.08% | 22.14% | 0.00 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 ANGO | 505.13M | 12.15 | -14.64 | -3.76% | -9.02% | -15.71% | ||
 PTGX | 7.26B | 112.86 | -55.05 | -89.41% | -6.48% | -17.76% | 0.02 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 |
Compare NSPR vs Peers
InspireMD, Inc. (NSPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NSPR Income Statement
InspireMD, Inc. (NSPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.76M | 3.6M | 3.72M | 2.48M | 4.5M | 5.17M | 6.21M | 7.01M | 8.98M |
Revenue Growth % | 45.78% | 30.42% | 3.33% | -33.22% | 80.89% | 15.04% | 20% | 12.96% | 28.11% |
Cost of Goods Sold | 2.18M | 2.61M | 2.96M | 2.4M | 3.74M | 4.05M | 4.4M | 5.5M | 6.33M |
COGS % of Revenue | 78.81% | 72.37% | 79.68% | 96.66% | 83.23% | 78.4% | 70.88% | 78.51% | 70.5% |
Gross Profit | 585K▲ 0% | 995K▲ 70.1% | 756K▼ 24.0% | 83K▼ 89.0% | 754K▲ 808.4% | 1.12M▲ 48.1% | 1.81M▲ 61.8% | 1.51M▼ 16.7% | 2.65M▲ 75.9% |
Gross Margin % | 21.19% | 27.63% | 20.32% | 3.34% | 16.77% | 21.6% | 29.12% | 21.49% | 29.5% |
Gross Profit Growth % | 473.53% | 70.09% | -24.02% | -89.02% | 808.43% | 48.14% | 61.77% | -16.66% | 75.9% |
Operating Expenses | 8.82M | 8.61M | 10.57M | 10.46M | 15.47M | 19.83M | 22.95M | 35.01M | 51.76M |
OpEx % of Revenue | 319.34% | 238.99% | 284.12% | 421.05% | 344.16% | 383.48% | 369.86% | 499.49% | 576.47% |
Selling, General & Admin | 7.54M | 7.07M | 7.62M | 8.23M | 10.31M | 12.02M | 14.97M | 21.38M | 37.26M |
SG&A % of Revenue | 273.13% | 196.36% | 204.73% | 331.19% | 229.41% | 232.45% | 241.24% | 304.97% | 414.97% |
Research & Development | 1.28M | 1.53M | 2.95M | 2.23M | 5.16M | 7.81M | 7.98M | 13.63M | 15M |
R&D % of Revenue | 46.22% | 42.63% | 79.39% | 89.86% | 114.75% | 151.03% | 128.62% | 194.52% | 167.09% |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -502K |
Operating Income | -8.23M▲ 0% | -7.61M▲ 7.5% | -9.82M▼ 29.0% | -10.38M▼ 5.7% | -14.72M▼ 41.8% | -18.71M▼ 27.2% | -21.14M▼ 13.0% | -33.5M▼ 58.5% | -49.11M▼ 46.6% |
Operating Margin % | -298.15% | -211.36% | -263.8% | -417.71% | -327.39% | -361.88% | -340.74% | -478% | -546.97% |
Operating Income Growth % | -7.64% | 7.54% | -28.97% | -5.75% | -41.77% | -27.16% | -12.99% | -58.46% | -46.59% |
EBITDA | -8.05M | -7.46M | -9.66M | -10.23M | -14.55M | -18.52M | -20.91M | -33.22M | -48.64M |
EBITDA Margin % | -291.71% | -207.14% | -259.55% | -411.63% | -323.8% | -358.25% | -337% | -474% | -541.66% |
EBITDA Growth % | -8.01% | 7.39% | -29.48% | -5.91% | -42.29% | -27.28% | -12.88% | -58.88% | -46.39% |
D&A (Non-Cash Add-back) | 178K | 152K | 158K | 151K | 161K | 188K | 232K | 280K | 476K |
EBIT | -8.29M | -7.61M | -9.82M | -10.38M | -14.72M | -18.71M | -21.14M | -33.5M | -49.11M |
Net Interest Income | -179K | 371K | -200K | -160K | -157K | 250K | 1.29M | 1.56M | 0 |
Interest Income | 0 | 371K | 0 | 0 | 0 | 250K | 1.29M | 1.56M | 0 |
Interest Expense | 179K | 0 | 200K | 160K | 157K | 0 | 0 | 0 | 0 |
Other Income/Expense | -179K | 371K | -200K | -160K | -157K | 250K | 1.29M | 1.56M | 389K |
Pretax Income | -8.41M▲ 0% | -7.24M▲ 13.9% | -10.02M▼ 38.3% | -10.54M▼ 5.2% | -14.87M▼ 41.1% | -18.46M▼ 24.1% | -19.85M▼ 7.5% | -31.95M▼ 60.9% | -48.72M▼ 52.5% |
Pretax Margin % | -304.64% | -201.06% | -269.18% | -424.14% | -330.88% | -357.05% | -319.92% | -455.79% | -542.63% |
Income Tax | 27K | 0 | 24K | 4K | 45K | 28K | 65K | 59K | 63K |
Effective Tax Rate % | -0.32% | 0% | -0.24% | -0.04% | -0.3% | -0.15% | -0.33% | -0.18% | -0.13% |
Net Income | -8.44M▲ 0% | -7.24M▲ 14.2% | -10.04M▼ 38.7% | -10.54M▼ 5.0% | -14.92M▼ 41.5% | -18.49M▼ 24.0% | -19.92M▼ 7.7% | -32.01M▼ 60.7% | -48.79M▼ 52.4% |
Net Margin % | -305.61% | -201.06% | -269.82% | -424.31% | -331.88% | -357.59% | -320.97% | -456.63% | -543.33% |
Net Income Growth % | 0.27% | 14.2% | -38.67% | -5.02% | -41.48% | -23.95% | -7.71% | -60.7% | -52.43% |
Net Income (Continuing) | -8.44M | -7.24M | -10.04M | -10.54M | -14.92M | -18.49M | -19.92M | -32.01M | -48.79M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -4265.93▲ 0% | -247.50▲ 94.2% | -72.00▲ 70.9% | -6.90▲ 90.4% | -2.03▲ 70.6% | -2.35▼ 15.8% | -0.82▲ 65.1% | -0.76▲ 7.3% | -0.76▲ 0.0% |
EPS Growth % | 97.18% | 94.2% | 70.91% | 90.42% | 70.58% | -15.76% | 65.11% | 7.32% | 0% |
EPS (Basic) | -4265.93 | -247.50 | -72.00 | -6.90 | -2.03 | -2.35 | -0.82 | -0.76 | -0.76 |
Diluted Shares Outstanding | 1.98K | 30.77K | 139.33K | 1.51M | 7.35M | 7.87M | 24.27M | 41.93M | 73.47M |
Basic Shares Outstanding | 1.98K | 30.77K | 139.33K | 1.51M | 7.35M | 7.87M | 24.27M | 41.93M | 73.47M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NSPR Balance Sheet
InspireMD, Inc. (NSPR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 5.16M | 11.42M | 7.81M | 15.34M | 37.09M | 21.33M | 44.16M | 40.52M | 61.47M |
Cash & Short-Term Investments | 3.71M | 9.38M | 5.51M | 12.64M | 34.04M | 17.8M | 39.02M | 34.64M | 54.21M |
Cash Only | 3.71M | 9.38M | 5.51M | 12.64M | 12M | 4.63M | 9.64M | 18.92M | 8.94M |
Short-Term Investments | 0 | 0 | 0 | 0 | 22.04M | 13.17M | 29.38M | 15.72M | 45.27M |
Accounts Receivable | 850K | 820K | 973K | 945K | 1.39M | 1.25M | 2.45M | 2.25M | 2.57M |
Days Sales Outstanding | 112.37 | 83.12 | 95.44 | 138.8 | 112.79 | 88.02 | 144.24 | 117.38 | 104.39 |
Inventory | 533K | 1.13M | 1.24M | 1.42M | 1.14M | 1.62M | 2.11M | 2.57M | 3.4M |
Days Inventory Outstanding | 89.4 | 158.83 | 152.16 | 215.02 | 111.52 | 145.95 | 174.78 | 170.46 | 195.82 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 952K | 869K | 2.07M | 2.44M | 2.62M | 3.33M | 3.48M | 6.29M | 7.93M |
Property, Plant & Equipment | 476K | 421K | 1.48M | 1.71M | 1.71M | 2.47M | 2.53M | 4.73M | 6.34M |
Fixed Asset Turnover | 5.80x | 8.55x | 2.51x | 1.45x | 2.62x | 2.09x | 2.45x | 1.48x | 1.42x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 476K | 448K | 586K | 725K | 905K | 856K | 951K | 1.55M | 1.59M |
Total Assets | 6.11M▲ 0% | 12.29M▲ 101.2% | 9.88M▼ 19.6% | 17.78M▲ 79.9% | 39.71M▲ 123.4% | 24.65M▼ 37.9% | 47.64M▲ 93.3% | 46.81M▼ 1.8% | 69.4M▲ 48.3% |
Asset Turnover | 0.45x | 0.29x | 0.38x | 0.14x | 0.11x | 0.21x | 0.13x | 0.15x | 0.13x |
Asset Growth % | -35.1% | 101.21% | -19.6% | 79.93% | 123.39% | -37.92% | 93.25% | -1.75% | 48.28% |
Total Current Liabilities | 2.48M | 2.92M | 3.12M | 3.71M | 4.35M | 5.07M | 6.02M | 7.68M | 10.71M |
Accounts Payable | 328K | 929K | 646K | 236K | 893K | 659K | 939K | 1.25M | 1.25M |
Days Payables Outstanding | 55.02 | 130.12 | 79.52 | 35.86 | 87.13 | 59.33 | 77.93 | 83.17 | 72.37 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 20K | 25K | 20K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.12M | 992K | 661K | 1.24M | 1.51M | 1.85M | 2.19M | 3.41M | 9.46M |
Current Ratio | 2.08x | 3.91x | 2.51x | 4.14x | 8.53x | 4.21x | 7.34x | 5.28x | 5.74x |
Quick Ratio | 1.86x | 3.52x | 2.11x | 3.76x | 8.27x | 3.89x | 6.99x | 4.94x | 5.42x |
Cash Conversion Cycle | 146.76 | 111.83 | 168.07 | 317.96 | 137.18 | 174.63 | 241.09 | 204.67 | 227.84 |
Total Non-Current Liabilities | 898K | 605K | 1.38M | 1.91M | 1.83M | 2.19M | 2.12M | 3.04M | 3.49M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 653K | 999K | 781K | 1.2M | 1.04M | 1.8M | 2.22M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 898K | 605K | 729K | 910K | 1.05M | 995K | 1.08M | 1.25M | 1.27M |
Total Liabilities | 3.38M | 3.52M | 4.5M | 5.61M | 6.18M | 7.26M | 8.14M | 10.72M | 14.2M |
Total Debt | 0 | 0 | 1.01M | 1.4M | 1.2M | 1.61M | 1.59M | 2.34M | 2.22M |
Net Debt | -3.71M | -9.38M | -4.5M | -11.25M | -10.8M | -3.02M | -8.04M | -16.58M | -6.71M |
Debt / Equity | - | - | 0.19x | 0.12x | 0.04x | 0.09x | 0.04x | 0.06x | 0.04x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | -46.32x | - | -49.08x | -64.88x | -93.73x | - | - | - | - |
Total Equity | 2.73M▲ 0% | 8.76M▲ 221.3% | 5.38M▼ 38.6% | 12.16M▲ 126.0% | 33.53M▲ 175.7% | 17.39M▼ 48.1% | 39.5M▲ 127.1% | 36.09M▼ 8.6% | 55.2M▲ 53.0% |
Equity Growth % | -32.58% | 221.34% | -38.57% | 125.95% | 175.69% | -48.13% | 127.11% | -8.65% | 52.97% |
Book Value per Share | 1378.67 | 284.80 | 38.63 | 8.04 | 4.56 | 2.21 | 1.63 | 0.86 | 0.75 |
Total Shareholders' Equity | 2.73M | 8.76M | 5.38M | 12.16M | 33.53M | 17.39M | 39.5M | 36.09M | 55.2M |
Common Stock | 0 | 4K | 0 | 0 | 1K | 1K | 2K | 3K | 4K |
Retained Earnings | -140.35M | -147.59M | -157.63M | -168.18M | -183.09M | -201.59M | -221.5M | -253.51M | -302.29M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NSPR Cash Flow Statement
InspireMD, Inc. (NSPR) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -8.13M | -7.61M | -9.81M | -9.08M | -13.21M | -15.54M | -16.38M | -21.87M | -35.1M |
Operating CF Margin % | -294.49% | -211.22% | -263.64% | -365.43% | -293.88% | -300.56% | -263.92% | -312% | -390.95% |
Operating CF Growth % | -8.49% | 6.46% | -28.98% | 7.43% | -45.47% | -17.65% | -5.37% | -33.54% | -60.52% |
Net Income | -8.44M | -7.24M | -10.04M | -10.54M | -14.92M | -18.49M | -19.92M | -32.01M | -48.79M |
Depreciation & Amortization | 178K | 152K | 158K | 151K | 161K | 188K | 232K | 280K | 476K |
Stock-Based Compensation | 672K | 70K | 325K | 606K | 1.58M | 2.35M | 4.49M | 10.14M | 12.33M |
Deferred Taxes | 28K | -14K | 89K | 177K | 74K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -511K | -392K | 8K | -4K | -28K | 14K | -381K | -1.02M | -231K |
Working Capital Changes | -60K | -182K | -350K | 533K | -75K | 395K | -801K | 736K | 1.11M |
Change in Receivables | -287K | -73K | -107K | 347K | -748K | 142K | -1.21M | 198K | -314K |
Change in Inventory | -33K | -601K | -102K | -179K | 272K | -478K | -485K | -464K | -826K |
Change in Payables | -290K | 584K | -283K | -410K | 657K | -234K | 280K | 315K | 1K |
Cash from Investing | -318K | -44K | -387K | -187K | -22.46M | 8.44M | -16.09M | 12.64M | -30.56M |
Capital Expenditures | -258K | -67K | -284K | -88K | -344K | -473K | -381K | -1.4M | -1.66M |
CapEx % of Revenue | 9.34% | 1.86% | 7.63% | 3.54% | 7.65% | 9.15% | 6.14% | 20% | 18.51% |
Acquisitions | 0 | 0 | 0 | 22K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -60K | 23K | -103K | -121K | -113K | -86K | -67K | 28.49M | 27.94M |
Cash from Financing | 4.63M | 13.37M | 6.33M | 16.39M | 35.03M | -140K | 37.53M | 18.45M | 55.57M |
Debt Issued (Net) | -2.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 6.82M | 13.37M | 6.33M | 16.39M | 35.03M | 0 | 37.53M | 1.6M | 55.57M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -3.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -10K | 0 | 0 | 0 | 0 | -140K | 0 | 16.85M | 0 |
Net Change in Cash | -3.81M▲ 0% | 5.67M▲ 249.1% | -3.87M▼ 168.2% | 7.13M▲ 284.3% | -641K▼ 109.0% | -7.37M▼ 1050.1% | 5.01M▲ 167.9% | 9.28M▲ 85.2% | -9.98M▼ 207.6% |
Free Cash Flow | -8.39M▲ 0% | -7.67M▲ 8.5% | -10.09M▼ 31.6% | -9.17M▲ 9.2% | -13.55M▼ 47.8% | -16.02M▼ 18.2% | -16.76M▼ 4.6% | -23.27M▼ 38.9% | -36.77M▼ 58.0% |
FCF Margin % | -303.84% | -213.08% | -271.27% | -368.97% | -301.54% | -309.71% | -270.06% | -332% | -409.46% |
FCF Growth % | -11.2% | 8.54% | -31.55% | 9.16% | -47.82% | -18.16% | -4.63% | -38.87% | -57.99% |
FCF per Share | -4241.15 | -249.37 | -72.45 | -6.06 | -1.85 | -2.03 | -0.69 | -0.55 | -0.50 |
FCF Conversion (FCF/Net Income) | 0.96x | 1.05x | 0.98x | 0.86x | 0.89x | 0.84x | 0.82x | 0.68x | 0.72x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NSPR Key Ratios
InspireMD, Inc. (NSPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -1539.76% | -249.2% | -126.02% | -141.95% | -120.19% | -65.29% | -72.62% | -70.01% | -84.68% | -106.88% |
Return on Invested Capital (ROIC) | - | - | - | -5598.48% | -864.52% | -93.35% | -75.65% | -69.2% | -98.61% | -108.34% |
Gross Margin | 5.39% | 21.19% | 27.63% | 20.32% | 3.34% | 16.77% | 21.6% | 29.12% | 21.49% | 29.5% |
Net Margin | -446.73% | -305.61% | -201.06% | -269.82% | -424.31% | -331.88% | -357.59% | -320.97% | -456.63% | -543.33% |
Debt / Equity | 0.66x | - | - | 0.19x | 0.12x | 0.04x | 0.09x | 0.04x | 0.06x | 0.04x |
Interest Coverage | -9.53x | -46.32x | - | -49.08x | -64.88x | -93.73x | - | - | - | - |
FCF Conversion | 0.89x | 0.96x | 1.05x | 0.98x | 0.86x | 0.89x | 0.84x | 0.82x | 0.68x | 0.72x |
Revenue Growth | -18.01% | 45.78% | 30.42% | 3.33% | -33.22% | 80.89% | 15.04% | 20% | 12.96% | 28.11% |
Related:NSPR Dividend History·NSPR Revenue History·NSPR Price History·NSPR P/E History·NSPR Financial Ratios·NSPR Institutional Holders
NSPR SEC Filings & Documents
InspireMD, Inc. (NSPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
NSPR Frequently Asked Questions
InspireMD, Inc. (NSPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
InspireMD, Inc. (NSPR) reported $9.0M in revenue for fiscal year 2025. This represents a 163% increase from $3.4M in 2009.
InspireMD, Inc. (NSPR) grew revenue by 28.1% over the past year. This is strong growth.
InspireMD, Inc. (NSPR) reported a net loss of $48.8M for fiscal year 2025.
Dividend & Returns
InspireMD, Inc. (NSPR) has a return on equity (ROE) of -106.9%. Negative ROE indicates the company is unprofitable.
InspireMD, Inc. (NSPR) had negative free cash flow of $36.8M in fiscal year 2025, likely due to heavy capital investments.